Coeptis Therapeutics, Inc.
COEP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.27 | 0.15 | -0.01 |
| FCF Yield | -62.80% | -1.80% | -0.89% | -3.05% |
| EV / EBITDA | -1.21 | -19.97 | -12.00 | -16.10 |
| Quality | ||||
| ROIC | -178.73% | -352.58% | -447.90% | -218.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.61 | 0.34 | 0.10 | 0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 421,616.33% |
| Free Cash Flow Growth | 8.15% | -86.79% | 37.88% | -98.95% |
| Safety | ||||
| Net Debt / EBITDA | -0.09 | 0.01 | 0.05 | -0.15 |
| Interest Coverage | -25.38 | -199.57 | -156.57 | -75.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -446.22 | -517.55 | -36.09 | 0.00 |